资源类型:
期刊
Pubmed体系:
Journal Article;Review
文章类型:
论著
单位:
[1]Department of Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
华中科技大学同济医学院附属同济医院
儿科学系
外科学系
小儿外科
ISSN:
1872-213X
关键词:
Crohn's disease
IBD
NF-kB
NOD
P38 MAPK
PI3K/Akt
Signaling pathway
TLR
Ulcerative colitis
摘要:
Inflammatory bowel disease (IBD) consists of Crohn's disease (CD) and ulcerative colitis (UC). It is thought to be caused by genetic, abnormal immune response of the intestinal immune system and dysfunction of intestinal mucosal barrier against enteric bacteria. Mutational genes can affect the development of IBDs via certain signaling pathways. The abnormal signaling pathways play an important role in the inflammatory process and can lead to dysregulation of the inflammatory response and are crucial in the pathogenesis of IBDs. The signaling pathways mainly include P38 MAPK, JNK MAPK, PI3K/Akt, NF-kB signaling pathways. Intestinal microorganisms play a key role in the initiation and maintenance of disease. Disorders of signaling pathways including TLR, NF-kB can act on the intestinal barrier, and cause uninhibitedly release of effector T cells which are the central cells mediating inflammation in CD. This review highlights relevant patents and a new insight of signaling pathways associated with IBDs will help to develop better therapeutic approaches. © 2010 Bentham Science Publishers Ltd.
PubmedID:
20001899
第一作者:
Wei, J
第一作者单位:
[1]Department of Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
通讯作者:
Feng, J
推荐引用方式(GB/T 7714):
Wei J,Feng J.Signaling pathways associated with inflammatory bowel disease[J].Recent patents on inflammation & allergy drug discovery.2010,4(2):105-17.doi:10.2174/187221310791163071.
APA:
Wei, J&Feng, J.(2010).Signaling pathways associated with inflammatory bowel disease.Recent patents on inflammation & allergy drug discovery,4,(2)
MLA:
Wei, J,et al."Signaling pathways associated with inflammatory bowel disease".Recent patents on inflammation & allergy drug discovery 4..2(2010):105-17